Navigation Links
Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
Date:4/17/2013

WASHINGTON, April 17, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that it has named Paolo Baroldi , M.D., Ph.D. as its Senior Vice President and Chief Medical Officer.

Dr. Baroldi has over 30 years of clinical development experience in many therapeutic areas, including neurology and psychiatry.  He has been working in the role of acting Chief Medical Officer with Vanda since October 1, 2012.

"We welcome Paolo to Vanda and look forward to his leadership in strengthening our clinical organization," said Mihael H. Polymeropoulos , M.D., President and Chief Executive Officer of Vanda.

Dr. Baroldi previously served as the Senior Vice President and Chief Medical Officer of Vanda from July 2006 through January 2009.  He has served in senior clinical development positions at Galileo Research, Supernus Pharmaceuticals, Chiesi Farmaceutici SpA, and Novartis AG.

Dr. Baroldi holds M.D. and Ph.D. degrees from the University of Milan, Italy and is a member of the board of directors of Galileo Research. 

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Company Contact

Jim Kelly
Senior Vice President  & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 Shimadzu Scientific Instruments ... acid analysis system developed jointly with Ajinomoto Co. ... can analyze 38 amino acids in nine minutes, ... achieves high-speed analysis utilizing a fast application-specific column ... accurate analytical results even under conditions with difficult ...
(Date:7/23/2014)... AVIV, Israel , July 23, 2014 /PRNewswire/ ... ., a portfolio company of Trendlines Agtech ... one of Israel,s leading ... http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines nanocrystalline ... plant pulp waste, with additional nanoparticles to produce ...
(Date:7/23/2014)...  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical cannabis research ... two medical marijuana dispensary locations in Las Vegas, ... Clark County, Nevada dispensary for which ... announced.  GrowBLOX Sciences, CEO Craig Ellins ... for dispensaries in the City of Las Vegas ...
(Date:7/23/2014)... a2z Inc. announces that AACC will ... Pathfinder, in its 2014 Annual Meeting & Clinical ... planned for July 29-31, 2014 in Chicago, IL at ... connect with global leaders in clinical chemistry, molecular diagnostics, ... of breaking science in laboratory medicine. , ChirpE Photo ...
Breaking Biology Technology:Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3
... agree that the promise of nanotechnology is great, but there ... , The new technology, which is making its way ... seen differently among scientists than the general public, with scientists ... broad categories of risk versus reward both groups seem to ...
... Combination of Two Proven Therapies that Significantly Raises ... ... Cholesterol, ABBOTT PARK, Ill., Feb. 15 ... first fixed-dose combination of two widely prescribed cholesterol,therapies, Niaspan(R) (Abbott,s proprietary ...
... ("PAREXEL") (Nasdaq: PRXL ) notes the recent movement ... "Company"). Under the,United Kingdom Takeover Code, PAREXEL confirms that ... ClinPhone in relation to a potential,offer by PAREXEL for ... of,ClinPhone. While that preliminary proposal was rejected by the ...
Cached Biology Technology:Nanotech's health, environmental impacts worry scientists and the public 2Nanotech's health, environmental impacts worry scientists and the public 3Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 2Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 3Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 4Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 5Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management 6Announcement in Relation to the Movement in the ClinPhone Share Price 2Announcement in Relation to the Movement in the ClinPhone Share Price 3Announcement in Relation to the Movement in the ClinPhone Share Price 4
(Date:7/23/2014)... MA -- What do mollusks, starfish, and corals ... habitat, they are all calcifiersorganisms that use calcium ... and shells for stability and protection. , The ... published by the Marine Biological Laboratory, addresses the ... changes worldwide. , As atmospheric carbon dioxide rises, ...
(Date:7/23/2014)... nasty habit of getting tangled and forming knots. Scientists ... how to disentangle them (e.g. useful for gene sequencing ... Advanced Studies (SISSA) in Trieste and his team have ... knots and their dynamics. In their latest paper, just ... together with Marco Di Stefano, first author and PhD ...
(Date:7/23/2014)... Currently, no cure exists for Alzheimer,s disease, the ... Americans. But scientists are now reporting new progress ... cancer treatment, that shows promise as a potential ... ACS, Journal of Medicinal Chemistry . , ... that in a healthy brain, the protein known ...
Breaking Biology News(10 mins):Calcification in changing oceans explored in special issue of The Biological Bulletin 2
... Scientists are reporting the first-ever data to show that ... function of heart cells, and that loss of the protein ... Published Feb. 26 in the Journal of Biological ... online Feb. 19, the research was led by scientists at ...
... on Antarctica,s rich marine life are presented this week ... (AAAS). Marine Biologist Huw Griffiths from British Antarctic Survey ... the distribution and abundance of Antarctica,s vast marine biodiversity ... Griffiths presents results from the census which began ...
... BETHESDA, Md. (Feb. 16, 2010) A few minor ... endurance, according to a new study from Physiological Genomics ... more likely to have variations of the NRF2 gene than ... have the genetic variations compared to sprinters, although the difference ...
Cached Biology News:Scientists identify critical enzyme in healthy heart function 2Understanding global climate change through new breakthroughs in polar research 2Study finds variations in 1 gene may be associated with endurance running 2
... A full-featured high-performance ICP-MS system designed for ... interface, Omega II off-axis ion lens, true ... 7500a can handle the widest range of ... the 7500a now includes as standard Agilents ...
... that it uses a deep-UV deuterium bulb, which ... with a shutter (controlled via a TTL signal ... DH-2000 Deuterium Tungsten Halogen Light Source combines ... light sources in a single optical path. The ...
One controller two vessel system suitable for early stage of fermentation, and small scale, Application : cultivation of microorganisms and human or animal cells...
... space and organize gloves, safety glasses, ... are the perfect benchtop storage bins ... processing and manufacturing. Clear static-dissipative PVC ... they attract. Many other sizes and ...
Biology Products: